2022/09/02 更新

写真a

カジ　ヒロユキ
梶　裕之
KAJI Hiroyuki
所属
糖鎖生命コア研究所 糖鎖ビッグデータセンター 数理解析部門 特任教授
職名
特任教授
 

論文 6

  1. Lewis glycosphingolipids as critical determinants of TRAIL sensitivity in cancer cells.

    Fukuoka T, Moriwaki K, Takamatsu S, Kondo J, Tanaka-Okamoto M, Tomioka A, Semba M, Komazawa-Sakon S, Kamada Y, Kaji H, Miyamoto Y, Inoue M, Bessho K, Miyoshi Y, Ozono K, Nakano H, Miyoshi E

    Oncogene     2022年8月

    　詳細を見る

    記述言語：英語  

    DOI： 10.1038/s41388-022-02434-3

    PubMed

  2. A Novel Method of CD31-Combined ABO Carbohydrate Antigen Microarray Predicts Acute Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation

    Tasaki M., Tateno H., Sato T., Tomioka A., Kaji H., Narimatsu H., Saito K., Nakagawa Y., Aoki T., Kamimura M., Ushiki T., Okada M., Miwa Y., Hotta K., Yoshida Y., Takahashi K., Tomita Y.

    Transplant International   35 巻   頁： 10248   2022年3月

    　詳細を見る

    記述言語：日本語   出版者・発行元：Transplant International  

    Isohemagglutinin assays employing red blood cells (RBCs) are the most common assays used to measure antibody titer in ABO-incompatible kidney transplantation (ABOi KTx). However, ABO antigens expressed on RBCs are not identical to those of kidney and antibody titers do not always correlate with clinical outcome. We previously reported that CD31 was the main protein linked to ABO antigens on kidney endothelial cells (KECs), which was different from those on RBCs. We developed a new method to measure antibody titer using a microarray of recombinant CD31 (rCD31) linked to ABO antigens (CD31-ABO microarray). Mass spectrometry analysis suggested that rCD31 and native CD31 purified from human kidney had similar ABO glycan. To confirm clinical use of CD31-ABO microarray, a total of 252 plasma samples including volunteers, hemodialysis patients, and transplant recipients were examined. In transplant recipients, any initial IgG or IgM antibody intensity >30,000 against the donor blood type in the CD31-ABO microarray showed higher sensitivity, specificity, positive predictive value, and negative predictive value of AABMR, compared to isohemagglutinin assays. Use of a CD31-ABO microarray to determine antibody titer specifically against ABO antigens expressed on KECs will contribute to precisely predicting AABMR or preventing over immunosuppression following ABOi KTx.

    DOI： 10.3389/ti.2022.10248

    Scopus

    PubMed

  3. Sensitive New Assay System for Serum <i>Wisteria floribunda</i> Agglutinin-Reactive Ceruloplasmin That Distinguishes Ovarian Clear Cell Carcinoma from Endometrioma.

    Sogabe M, Kojima S, Kaya T, Tomioka A, Kaji H, Sato T, Chiba Y, Shimizu A, Tanaka N, Suzuki N, Hayashi I, Mikami M, Togayachi A, Narimatsu H

    Analytical chemistry   94 巻 ( 5 ) 頁： 2476 - 2484   2022年2月

    　詳細を見る

    記述言語：英語  

    DOI： 10.1021/acs.analchem.1c04302

    PubMed

  4. O-glycosylated HBsAg peptide can induce specific antibody neutralizing HBV infection

    Angata K., Wagatsuma T., Togayachi A., Sato T., Sogabe M., Tajiri K., Ozawa T., Nagashima I., Shimizu H., Iijima S., Korenaga M., Kuno A., Kaji H., Mizokami M., Narimatsu H.

    Biochimica et Biophysica Acta - General Subjects   1866 巻 ( 1 ) 頁： 130020   2022年1月

    　詳細を見る

    記述言語：日本語   出版者・発行元：Biochimica et Biophysica Acta - General Subjects  

    Background: Hepatitis B virus (HBV), which causes hepatitis, liver cirrhosis, and hepatocellular carcinoma, is a global human health problem. HBV contains three envelope proteins, S-, M-, and L-hepatitis B surface antigen (HBsAg). We recently found that O-glycosylated M-HBsAg, reactive with jacalin lectin, is one of the primary components of HBV DNA-containing virus particles. Thus, we aimed to analyze and target the glycosylation of HBsAg. Methods: HBsAg prepared from the serum of Japanese patients with HBV were analyzed using mass spectrometry. The glycopeptide modified with O-glycan was generated and used for immunization. The specificity of the generated antibody and the HBV infection inhibition activity was examined. Results: Mass spectrometry analysis revealed that T37 and/or T38 on M-HBsAg of genotype C were modulated by ±NeuAc(α2,3)Gal(β1,3)GalNAc. Chemically and enzymatically synthesized O-glycosylated peptide (Glyco-PS2) induced antibodies that recognize mainly PreS2 in M-HBsAg not in L-HBsAg, whereas the non-glycosylated peptide (PS2) induced antisera recognizing L-HBsAg but not O-glycosylated M-HBsAg. The removal of O-glycan from M-HBsAg partly decreased the reactivity of the Glyco-PS2 antibody, suggesting that peptide part was also recognized by the antibody. The antibody further demonstrated the inhibition of HBV infection in human hepatic cells in vitro. Conclusions: Glycosylation of HBsAg occurs differently in different HBsAgs in a site-specific manner. The new Glyco-PS2 antibody, recognizing O-glycosylated M-HBsAg of genotype C, could inhibit HBV infection. General significance: The detailed analysis of HBsAg identified different glycosylations of HBV surface. The glycosylated peptide based on mass spectrometry analysis showed higher potential to induce functional antibody against HBV.

    DOI： 10.1016/j.bbagen.2021.130020

    Scopus

    PubMed

  5. Host-Dependent Producibility of Recombinant <i>Cypridina noctiluca</i> Luciferase With Glycosylation Defects.

    Mitani Y, Yasuno R, Kihira K, Chung K, Mitsuda N, Kanie S, Tomioka A, Kaji H, Ohmiya Y

    Frontiers in bioengineering and biotechnology   10 巻   頁： 774786   2022年

    　詳細を見る

    記述言語：英語  

    DOI： 10.3389/fbioe.2022.774786

    PubMed

  6. Tamoxifen-resistant breast cancer cells exhibit reactivity with Wisteria floribunda agglutinin.

    Hlaing MT, Horimoto Y, Denda-Nagai K, Fujihira H, Noji M, Kaji H, Tomioka A, Ishizuka Y, Saeki H, Arakawa A, Saito M, Irimura T

    PloS one   17 巻 ( 8 ) 頁： e0273513   2022年

    　詳細を見る

    記述言語：英語  

    DOI： 10.1371/journal.pone.0273513

    PubMed

▼全件表示

論文の先頭へ▲